1 Min Read
Aug 17 (Reuters) - Trillium Therapeutics Inc
* Trillium Therapeutics receives FDA clearance to proceed with TTI-621 in clinical trial targeting solid tumors and mycosis fungoides Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.